A Study for PRO of CML in Real Word

Validation Value of the Questionnaire to Assess Health-related Quality of Life in Patients With CML

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05092048

Acronym

Case-Only

Enrollment

10000

Registered

2021-10-25

Start date

2021-09-22

Completion date

2022-10-01

Last updated

2021-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CML (Chronic Myelogenous Leukemia)

Brief summary

Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.

Detailed description

1. Above 18 years of age. 2. Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML). 3. Written informed consent. 4. Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible.

Interventions

OTHERquestionnaire

PHQ-9 and GAD-7 questionnaire

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Design outcomes

Primary

Measure	Time frame	Description
Assess health-related Quality of Life and Symptom Burden in patients with chronic myeloid leukemia	1 year	Health-related quality of life (HRQOL) assessment in the current treatment landscape of chronic myeloid leukemia

Countries

China

Contacts

Primary Contactna xu, doctor

292347668@qq.com02062787883

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026